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Abstract
Background: CD33 is a membrane receptor containing a lectin domain and a cytoplasmic immunoreceptor
tyrosine-based inhibitory motif (ITIM) that is able to inhibit cytokine production. CD33 is expressed by monocytes,
and reduced expression of CD33 correlates with augmented production of inflammatory cytokines, such as IL-1b,
TNF-a, and IL-8. However, the role of CD33 in the inflammation associated with hyperglycemia and diabetes is
unknown. Therefore, we studied CD33 expression and inflammatory cytokine secretion in freshly isolated
monocytes from patients with type 2 diabetes. To evaluate the effects of hyperglycemia, monocytes from healthy
donors were cultured with different glucose concentrations (15-50 mmol/l D-glucose), and CD33 expression and
inflammatory cytokine production were assessed. The expression of suppressor of cytokine signaling protein-3
(SOCS-3) and the generation of reactive oxygen species (ROS) were also evaluated to address the cellular
mechanisms involved in the down-regulation of CD33.
Results: CD33 expression was significantly decreased in monocytes from patients with type 2 diabetes, and higher
levels of TNF-a, IL-8 and IL-12p70 were detected in the plasma of patients compared to healthy donors. Under
high glucose conditions, CD33 protein and mRNA expression was significantly decreased, whereas spontaneous
TNF-a secretion and SOCS-3 mRNA expression were increased in monocytes from healthy donors. Furthermore, the
down-regulation of CD33 and increase in TNF-a production were prevented when monocytes were treated with
the antioxidant a-tocopherol and cultured under high glucose conditions.
Conclusion: Our results suggest that hyperglycemia down-regulates CD33 expression and triggers the
spontaneous secretion of TNF-a by peripheral monocytes. This phenomenon involves the generation of ROS and
the up-regulation of SOCS-3. These observations support the importance of blood glucose control for maintaining
innate immune function and suggest the participation of CD33 in the inflammatory profile associated with type 2
diabetes.
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Background
Both acute and chronic hyperglycemia are associated
with inflammation [1]. Patients with newly diagnosed or
established diabetes mellitus (DM) have significantly
higher levels of acute-phase proteins and pro-inflamma-
tory cytokines compared to control subjects without
DM [2-5]. Monocytes isolated from patients with type 1
diabetes produce increased levels of IL-6, IL-1b and che-
mokines of the CXC family including IL-8 and inter-
feron gamma-induced protein 10 (IP-10) [6].
Furthermore, monocytes from patients with DM pro-
duce higher levels of TNF-a and IL-8 in comparison to
control monocytes [7-9].
TNF-a p r o d u c t i o ni st h o u g h tt op l a yar o l ei nt h e
generation of microvascular complications associated
with diabetes, e.g., by enhancing chronic eye
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chronic inflammation, TNF-a regulates glucose and
lipid metabolism and inhibits insulin production in pan-
creatic beta cells [12]. TNF-a is also produced in adi-
pose tissue.
In both clinical and experimental conditions, hypergly-
cemia has been shown to alter many cellular parameters.
This metabolic state leads to the generation of reactive
oxygen species (ROS), the activity of protein kinase C
(PKC), and the expression of p38 mitogen-activated pro-
tein kinase, nuclear factor B( N F - B), inflammatory
cytokines, and chemokines [13-15].
Diverse mechanisms have been proposed to explain
how hyperglycemia contributes to inflammation. For
example, PKC activity may be increased secondarily to a
poorly reversible, non-enzymatic protein glycation pro-
cess, which could lead to the irreversible production of
advanced glycation end products (AGEs). AGEs are
known to stimulate the production of inflammatory
cytokines in monocytes and macrophages through the
activation of a specific receptor for AGEs (RAGE)
[16,17]. Additionally, hyperglycemia may stimulate the
production of inflammatory cytokines by increasing the
levels of peroxides and free radicals. High serum con-
centrations of glucose can lead to enhanced glycolysis
and mitochondrial overproduction of superoxide anion
(O2
-) and other reactive oxygen species (ROS), which
directly induce the activation of protein kinase C (PKC)
and nuclear factor B( N F - B) [18,19]. Indeed, these
transcription factors have been shown to induce the
release of IL-1b and IL-6 by human monocytes cultured
under high glucose conditions [20]. The secondary
effects of PKC and NF- B activation resulting from
hyperglycemia can further amplify the inflammatory
response, resulting in the production of the chemokine
IP-10 and the up-regulated expression of TLR2 and
TLR4 [6].
Although these mechanisms can partially explain the
high levels of inflammatory cytokines observed under
acute hyperglycemic conditions, the effects of high glucose
on other regulatory molecules involved in the control of
inflammatory cytokine production have not yet been iden-
tified. Low membrane expression levels of CD33 have
been associated with higher levels of inflammatory cyto-
kine production, and CD33 is expressed by myeloid pro-
genitor cells of the bone marrow as well as peripheral
blood monocytes and lymphocytes [21,22]. CD33, which is
also referred to as human sialic acid-binding Ig superfam-
ily lectin (hSiglec-3), is a member of the Siglec family that
includes 11 human proteins of I-type (Ig-type) lectins with
a V-set Ig-like domain and varying numbers of C2-set Ig-
like domains, such as sialoadhesins (Siglec-1 and CD169),
CD22 (Siglec-2), myelin-associated glycoprotein (MAG;
Siglec-4), and additional members from a subgroup that
contains CD33 (Siglec-3) and CD33-related Siglecs
(Siglec-5 to -11) [22-25].
The regulation of cytokine production via CD33 is
believed to depend on two putative conserved tyrosine-
based signaling motifs contained within the cytosolic tail
of CD33. These signaling motifs, known as immunore-
ceptor tyrosine-based inhibitory motifs (ITIMs), act as
regulatory elements that inhibit signaling [22]. CD33
activity is regulated by SOCS3, which is a member of
the suppressor of cytokine signaling (SOCS) protein
family. The binding of SOCS3 to the phosphorylated
ITIM of CD33 induces the proteosomal degradation of
both molecules [26], and the reduction of CD33 surface
expression on monocytes by silencing with small inter-
fering RNA (siRNA) or antibody blockade results in the
increased secretion of IL-1b, IL-8, and TNF-a [27].
Interestingly, the role of CD33 in the production of
pro-inflammatory cytokines secondary to hyperglycemia
has not yet been explored. Thus, the aim of the current
study was to examine the effects of high glucose concen-
trations on the expression of CD33 and the production
of cytokines in human monocytes from healthy indivi-
duals. Additionally, from patients with type 2 diabetes,
the levels of CD33 expression on freshly obtained mono-
cytes and serum cytokine levels were evaluated and com-
pared to those from healthy individuals. Our results show
that under hyperglycemic conditions, monocytes CD33
mRNA and surface protein expression was decreased,
whereas TNF-a production was increased. These changes
were inhibited by antioxidant pre-treatment, suggesting
that the hyperglycemic-dependent decrease in CD33
expression involves the generation of oxidative stress.
Results
The clinical characteristics of the studied subjects are
summarized in Table 1. There were no significant differ-
ences in gender, age, BMI, or the levels of creatinine or
LDL or HDL cholesterol between the control group and
the type 2 diabetes group. The levels of glucose, HbA1c
and triglycerides were significantly higher among type 2
diabetes subjects than control subjects. Most patients
with type 2 diabetes had received metformin and Glib-
enclamide. Only one of the diabetes patients had
received metoprolol, and another had been administered
clonazepam and levopromazine. None of the patients
had been prescribed angiotensin receptor blockers, insu-
lin, or statins. Healthy donors did not have any infec-
tions or inflammatory diseases and did not take any
medications during the study period.
Diminished CD33 expression in monocytes from patients
with type 2 diabetes
To determine whether CD33 expression is decreased in
freshly isolated peripheral monocytes from type 2
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flow cytometry and qPCR studies were performed. As
shown in Figure 1, a significant decrease in the cell sur-
face expression of CD33 was detected in monocytes
obtained from patients with type 2 diabetes, as com-
pared to those from healthy volunteers (P < 0.05) (Fig-
ure 1A and 1B).
In addition, CD33 mRNA expression was also reduced
in monocytes from type 2 diabetes patients (Figure 1C).
Because CD33 is a regulator of cytokine production,
these findings suggest that low levels of CD33 expression
could be involved in the elevated inflammatory cytokine
production observed in patients with type 2 diabetes.
Increased pro-inflammatory cytokine levels in plasma
from patients with type 2 diabetes
We next measured the levels of pro-inflammatory cyto-
kines in the blood plasma of type 2 diabetes patients
and healthy subjects. As shown in Figure 2, all of the
pro-inflammatory cytokines evaluated (IL-1b, IL-6, IL-8,
IL-10, IL-12p70, and TNF-a) were increased in patients
with type 2 diabetes, although only the increases in
TNF-a, IL-8, and IL-12 p70 were statistically significant
in comparison to healthy individuals (P < 0.05) (Figure
2A). In addition, TNF-a production by monocytes was
assessed by quantitative real time PCR (qPCR), and
monocytes from patients with type 2 diabetes had signif-
icantly elevated levels of TNF-a mRNA than controls (P
< 0.05) (Figure 2B).
High glucose conditions down-regulate the surface
expression of CD33 in cultured monocytes
CD33 is known to play a role in the regulation of
cytokine production, and low levels of CD33 expres-
sion have been associated with high levels of inflam-
matory cytokine production. Therefore, using flow
cytometry, we measured the relative levels of CD33
surface expression on peripheral monocytes that were
isolated from healthy volunteers and cultured in the
presence of low or high concentrations of D-glucose.
As shown in Figures 3A and 3B, culturing monocytes
with 30 or 50 mmol/l D-glucose for 7 days induced a
significant decrease in CD33 expression on the cell
surface, compared to culture conditions containing
5.5 mmol/l D-glucose (P < 0.05). CD33 mRNA
expression was also decreased in monocytes cultured
for 7 days under high glucose conditions. As shown
in Figure 3C, CD33 mRNA expression was signifi-
cantly reduced in monocytes cultured in 15, 30 or 50
mmol/l D-glucose, compared to those cultured under
normal glucose conditions (5.5 mmol/l D-glucose) (P
<0 . 0 5 ) .
High glucose conditions induce pro-inflammatory
cytokine production
Previous studies have shown that high glucose concen-
trations in vitro induce the production of greater
amounts of IL-6 [20], which is a cytokine that can regu-
late CD33 expression [28]. Therefore, we evaluated the
long-term effects (7 days) of high glucose conditions on
the levels of interleukin-1b (IL-1b), interleukin-6 (IL-6),
interleukin-8 (IL-8), interleukin-10 (IL10), interleukin-
12p70 (IL-12p70), and tumor necrosis factor (TNF-a)
released into the supernatants of cultured monocytes
using flow cytometry. In addition, we examined the
levels of cytokine mRNA using qPCR. Concentrations of
15 and 30 mmol/l D-glucose did not induce the produc-
tion of pro-inflammatory cytokines (data not shown).
However, 50 mmol/l D-glucose significantly induced
both TNF-a secretion (P < 0.05) and TNF-a mRNA
expression, compared to 5.5 mmol/l D-glucose (P <
0.05) (Figure 4A and 4B). In addition, an increase in IL-
12 p70 expression was observed, although it did not
reach statistical significance. The levels of IL-1b,I L - 6
and IL-10 were not increased under these conditions.
These results suggest that the low levels of CD33
expression observed in monocytes cultured in high con-
centrations of D-glucose were not the result of autocrine
IL-1b, IL-6, IL-8 or IL-10 production. Nonetheless, the
reduction in CD33 mRNA and cell surface protein
expression may be associated with high levels of TNF-a
production.
Table 1 Demographic characteristics and clinical data of
the groups
Type 2
diabetes
Healthy P value
n2 1 2 6
Gender (M/F) 8/13 6/20 0.0832
Age (years) 51.16 (10.17) 48.48 (9.42) 0.1868
BMI (kg/m
2) 27.85 (4.64) 28.32 (2.22) 0.4579
Glucose (mg/dl) 265.30 (79.71) 96.28 (9.19) < 0.0001
*
Creatinine (mg/dl) 0.70 (0.24) 0.76 (0.12) 0.0757
Cholesterol (mg/dl) 211.50 (37.15) 212.00 (43.44) 0.4547
Triglycerides (mg/dl) 295.50 (297.10) 198.00
(116.80)
0.0171 *
LDL cholesterol (mg/dl) 129.30 (37.29) 134.60 (34.26) 0.5
HDL cholesterol (mg/dl) 45.16 (8.96) 46.08 (12.23) 0.4019
Hb1Ac (%) 10.42 (2.04) 5.58 (0.25) < 0.0001
*
Time since diagnosis
(years)
7-
Data are means SD. *P values correspond to the differences between healthy
and type 2 diabetes
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Figure 1 CD33 expression in human monocytes from type 2 diabetes patients. (A) Monocytes were stained with anti-CD3, CD14 and CD33
mAbs. At least 50,000 events were acquired for the flow cytometry analysis. CD33 expression is shown after gating for the CD3-CD14+ cells, and
a histogram of CD33 expression was plotted for type 2 diabetes patients (tinted histogram) and healthy subjects (open histogram). (B) A bar
graph showing the mean intensity fluorescence (MFI) data for CD33 expression in freshly isolated monocytes from patients with type 2 diabetes
(n = 10) and healthy donors (n = 10). The data are presented as the mean ± SD. * P < 0.05 compared to healthy donors. (C) Monocytes from
type 2 diabetes patients (n = 9) and healthy donors (n = 8) were evaluated using Taqman gene expression analysis for CD33 mRNA expression.
The results were analyzed according to the ΔΔCt method, and the data are presented as the mean ± SD. * P < 0.05 compared to healthy
donors.
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Figure 2 Pro-inflammatory cytokine production in type 2 diabetes patients. Plasma from type 2 diabetes patients and healthy controls was
tested for the presence of pro-inflammatory cytokines using the CBA kit for IL-8, IL-1b, IL-6, IL-10, IL-12p70 and TNF-a. (A) The bar graphs show
the quantification of these cytokines for type 2 diabetes patients (n = 14) and healthy controls (n = 10). All data are presented as the mean ±
SD. * P < 0.05 compared to healthy donors. (B) The expression of TNF-a mRNA and 18 S ribosomal RNA was analyzed for monocytes collected
from type 2 diabetes patients (n = 7) and healthy subjects (n = 9). The results are expressed according to the ΔΔCt method, and the data are
presented as the mean ± SD. * P < 0.05 compared to healthy donors.
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Figure 3 High glucose concentrations down-regulate CD33 expression in human monocytes. Monocytes from healthy donors were
cultured in the presence of D-glucose (5.5, 15, 30, or 50 mmol/l) for 7 days. (A) Representative histograms show the expression of CD33 in
monocytes cultured with 5.5 mmol/l (gray), 15, 30, or 50 mmol/l (open histogram) D-glucose. (B) Bar graphs show the MFI of CD33 in
monocytes cultured under high glucose compared to those cultured in normal medium. The data are presented as the mean ± SD (n = 6). (C)
Taqman gene expression mRNA analysis of CD33 and 18 S ribosomal RNA expression. The results were analyzed according to the ΔΔCt method,
and all data are presented as the mean ± SD (n = 3). * P < 0.05 compared to 5.5 mmol/l D-glucose.
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under high glucose conditions
To investigate whether the observed increase in TNF-a
production was mediated by an effect of high glucose
concentrations on CD33 expression in monocytes, we
assessed the production of TNF-a in monocytes expres-
sing low or high levels of CD33. As shown in Figure 5A,
50 mmol/l D-glucose increased the relative percentage of
CD33
low monocytes, thereby decreasing the fraction of
CD33
high cells. However, both populations demonstrated
increased TNF-a production. Thus, these results indicate
that in vitro hyperglycemia induces the overproduction
of TNF-a in both CD33
low and CD33
high monocytes.
However, the frequency of TNF-a-producing cells was
significantly higher in the CD33
low subset (Figure 5B).
CD33 down-regulation and TNF-a production is
prevented by a-tocopherol treatment
The generation of ROS resulting from high concentra-
tions of glucose is believed to contribute to hypergly-
cemia-induced inflammatory responses. Thus, we
assessed whether ROS generation was involved in the
production of TNF-a and CD33 expression by human
monocytes cultured under high glucose conditions. As
shown in Figure 6A, the generation of ROS by glucose
was dose-dependent, and this effect was prevented by
co-incubation with a-tocopherol, a compound known
to reduce ROS generation and TNF-a production
[29,30]. Additionally, a -tocopherol treatment pre-
vented the decrease in surface CD33 expression by
monocytes (Figure 6B), the up-regulation of TNF-a
mRNA expression, and the secretion of TNF-a
induced by high glucose conditions (Figure 6C). Thus,
these results suggest that ROS generation induced by
high glucose concentrations is responsible for the
down-regulation of CD33 expression and spontaneous
production of TNF-a.
High glucose concentrations induce the expression of
suppressor of cytokine signaling 3 (SOCS3) in monocytes
Recent studies have demonstrated that high glucose
concentrations increase the expression of SOCS3
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Figure 4 Effect of high glucose concentrations on pro-inflammatory cytokine production. Supernatants from monocytes cultured in the
presence of 5.5 and 50 mmol/l D-glucose for 7 days were used for the quantification of IL-8, IL-1b, IL-6, IL-10, IL-12p70 and TNF-a protein levels.
(A) The bar graphs represent the quantification of cytokine production (n = 3). (B) The expression of TNF-a mRNA from monocytes cultured in
high glucose. TNF-a mRNA and 18 S ribosomal RNA expression was analyzed by qPCR, and the results are expressed according to the ΔΔCt
method. The data are presented as the mean ± SD for all graphics (n = 3). * P < 0.05 compared to treatment with 5.5 mmol/l D-glucose.
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Figure 5 TNF-a production in CD33
lowand CD33
highmonocytes. Monocytes from healthy donors were cultured in the presence of glucose
for 7 days and were then stained with anti-human CD33 and anti-human TNF-a antibodies. (A) Representative dot-plots show the percentages
of TNF-a-producing CD33
low and CD33
high monocytes that were cultured with either 5.5 mmol/l (left) or 50 mmol/l (right) D-glucose (B) The bar
graph summarizes the levels of TNF-a production by CD33
low (white) and CD33
high (black) monocytes cultured with 50 mmol/l D-glucose (n =
4). The data are expressed as the mean ± SD. * P < 0.05 as compared to the TNF-a production by CD33
low and CD33
high
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Page 8 of 14mRNA in mononuclear cells [31,32]. Furthermore,
SOCS3 has been shown to induce proteosomal degra-
dation of CD33 in adherent monolayers of human
cells [26]. Thus, we evaluated SOCS3 mRNA expres-
sion in monocytes cultured under hyperglycemic con-
ditions for 2, 24, 48 h and 7 days. As shown in Figure
7, the levels of SOCS3 mRNA increased after 48 h of
culture in the presence of high glucose concentrations
(50 mmol/l). Although the levels of SOCS3 mRNA
had decreased after 7 days of culture, the levels
detected at this time remained greater than those in
monocytes cultured in 5.5 mmol/l D-glucose. These
results suggest that the down-regulation of cell surface
CD33 expression mediated by high glucose concentra-
tions may be regulated by increased levels of SOCS3
protein.
Discussion
The primary finding of our study is that CD33 cell sur-
face protein and mRNA expression levels are signifi-
cantly reduced in monocytes from patients with type 2
diabetes. The analysis of the plasma cytokine profile of
patients with type 2 diabetes showed that pro-inflamma-
tory cytokine levels were increased, although only the
levels of IL-8, IL-12, and TNF-a were significantly
increased when compared to healthy volunteers. These
results suggest that the elevated levels of pro-inflamma-
tory cytokines in the serum of patients with type 2 dia-
betes could be related to the down-regulated expression
of CD33. Increased levels of pro-inflammatory cytokines
in the plasma of patients with type 2 diabetes have been
widely reported [5,9,33]. On the other hand, sponta-
neous production of TNF-a, IL-6, and IL-8 was
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Figure 6 The effect of a-tocopherol treatment on monocyte CD33 expression andTNF-a production. Monocytes from healthy donors
were cultured in 50 mmol/l D-glucose either with or without a-tocopherol for 7 days. (A) Representative histogram of ROS generation from
monocytes cultured with 5.5 mmol/l (gray) or 50 mmol/l D-glucose (open histogram) without a-tocopherol (left) or with a-tocopherol (right).
The bar graph shows relative ROS generation (n = 6). (B) A representative histogram showing CD33 expression from monocytes cultured without
(left) or with a-tocopherol (right). The bar graph shows the relative CD33 expression levels (n = 3). (C) Left panel, the production of TNF-a,a s
measured by flow cytometry. Right panel, relative fold change of TNF-a mRNA expression with and without a-tocopherol treatment (n = 3). All
data are expressed as the mean ± SD. * P < 0.05 compared to treatment with 5.5 mmol/l D-glucose.
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or by decreasing CD33 surface expression by RNA inter-
ference [27]. Although diverse mechanisms have been
proposed to explain the increase of inflammatory cyto-
kines in patients with type 2 diabetes, to our knowledge,
this is the first study to describe an association between
CD33 and the inflammatory cytokine profile in type 2
diabetes patients.
This study also demonstrated that high glucose con-
centrations in vitro resulted in decreased expression of
CD33 protein and mRNA in human monocytes from
healthy donors.
In addition, we observed a significant increase in levels
of TNF-a present in the supernatants of monocytes cul-
tured under high glucose conditions (50 mmol/l D-glu-
cose), although this increase was not observed for other
cytokines. Increased levels of TNF-a mRNA from
monocytes cultured with 33 mmol/l glucose have pre-
viously been described for healthy individuals [3]. In
addition, we did not detect an effect of high glucose
concentrations on the production of IL-1b or IL-6 in
monocytes. However, previous studies have reported
inconsistent results; some have shown that hyperglyce-
mia increases the production of IL-1b and IL-6 in the
THP-1 cell line, whereas others have shown that hyper-
glycemia only induces the production of IL-6 in primary
human monocytes [20,34]. In addition, other studies
have demonstrated reduced IL-1b levels in RAW264
murine macrophages exposed to 8-20 mmol/l D-glucose
[35]. These differences may be related to differences in
the cell types, glucose concentrations or lengths of cul-
ture time used to measure cytokine levels. Other authors
reported that high glucose concentration and LPS treat-
ment act synergistically for stimulate the secretion of
inflammatory cytokines in peripheral mononuclear cells
from humans [36,37]. Consistent with the formerly
mentioned data from other authors, our results pre-
sented here serve to extend previous knowledge of the
role of high glucose concentrations on the promotion of
inflammation by demonstrating the in vitro effects of
high glucose concentrations on TNF-a production by
human monocytes.
We also presented evidence demonstrating that high
glucose concentrations in vitro could increase the pro-
portion of CD33
low monocytes and reduce the propor-
tion of CD33
high monocytes, although TNF-a
production was increased in both cell populations.
These results support the idea that hyperglycemia leads
to an increase in TNF-a production through a CD33-
mediated mechanism, although there are likely addi-
tional mechanisms involved in production of TNF-a
that are beyond the scope of this study. Furthermore,
the spontaneous production of IL-6 by CD33
-/lowplasma-
cytoid dendritic cells from patients with diabetes with-
out atherosclerotic complications has been reported
[38]. These findings suggest that the increased produc-
tion of pro-inflammatory cytokines in patients with type
2 diabetes may be partially associated with the subpopu-
lation of CD33
low monocytes.
The precise mechanisms by which hyperglycemia
down-regulates CD33 expression have not yet been elu-
cidated, although the generation of ROS by high glucose
concentrations is believed to contribute to hyperglyce-
mia-induced inflammatory responses [19,29,30]. Thus,
we explored the association between ROS generation
and CD33 expression in monocytes cultured under high
glucose concentrations and treated with a-tocopherol.
The results showed that a-tocopherol decreased ROS
generation and prevented the effect of high glucose on
CD33 expression. This result supports the idea that the
oxidative stress generated by high glucose concentra-
tions contributes to the down-regulation of CD33.
We observed an inhibition of TNF-a production in
monocytes that were cultured under conditions of high
glucose and were treated with a-tocopherol. This result
indicates that ROS generation is involved in the TNF-a
production by human monocytes cultured under high
glucose conditions. Thus, the low expression of CD33
and the inhibition of TNF-a production in monocytes
cultured under high glucose concentrations are primar-
ily related to ROS generation. Therefore, we propose
that ROS generation induced by high glucose conditions
Figure 7 Expression of SOCS3 mRNA in monocytes. Monocytes
from healthy donors were cultured in 5.5 or 50 mmol/l D-glucose
for 2, 24, or 48 hours or 7 days, and the expression levels of SOCS3
mRNA and 18 S ribosomal RNA were evaluated using the Taqman
gene assay. Gene expression was normalized to that of the
housekeeping gene, and the results are expressed according the
ΔΔCt method as the relative fold-change with respect to cells
treated with 5.5 mmol/l D-glucose. The data are presented as the
mean ± SD (n = 3). * P < 0.05.
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sion. Alternatively, ROS generation could induce the
production of pro-inflammatory cytokines that could
then regulate the expression of CD33. A study by Sham-
sasenjan et al. postulated that IL-6 down-regulates CD33
expression in myeloma cells [28]. However, in the cur-
rent study, IL-6 production was not increased in the
supernatants of monocytes cultured under high glucose
conditions, and therefore, IL-6 is likely not the mechan-
ism responsible for CD33 regulation under hyperglyce-
mic conditions.
In this study, we also showed that high glucose con-
centrations could up-regulate the expression of SOCS3
mRNA in human monocytes, suggesting that this mole-
cule may regulate the levels of monocyte CD33 expres-
s i o n .T h i sh y p o t h e s i si sc o n s i s t e n tw i t hr e s u l t ss h o w i n g
that SOCS3 could contribute to CD33 degradation in
peripheral monocytes [26]. Recently, it was reported
that glucose ingestion induces the over-expression of
SOCS3 in peripheral monocytes [31,32,39]. Interestingly,
SOCS3 expression is induced by TNF-a and could
therefore represent a feedback mechanism for inflamma-
tion associated with CD33 regulation [40,41]. However,
further studies are needed to assess whether TNF-a
production regulates SOCS3 expression and its effect on
CD33 expression.
Our study had limitations, the most critical of which
was the limited ability of our in vitro model to recapitu-
late what occurs in patients with type 2 diabetes. None-
theless, we demonstrated that a significant increase in
TNF-a production and decrease in CD33 protein and
mRNA expression were induced by high concentrations
of glucose (30-50 mmol/l). A concentration of 50
mmol/l is equivalent to 900 mg/dl of blood glucose,
which is a concentration that is rarely attained in type 2
diabetes patients is much greater than the mean value
found in the diabetes patients included in this study
(265.3 ± 79.71 mg/dl or 14.73 ± 4.42 mmol/l blood glu-
cose). Hence, it is possible that the glucose sensitivity of
TNF-a production associated with CD33 expression is
greater in vivo than in vitro. However, this increased
level of sensitivity may occur if other factors in vivo
could potentiate glucose-induced ROS generation.
Further studies are required to examine this possibility.
The increase in TNF-a associated with the down-regula-
tion of CD33 expression presented here constitutes an
interesting in vitro model to further investigate the
molecular processes involved in the modulation of
inflammation by glucose.
Conclusion
We conclude that hyperglycemic conditions induce the
down-regulation of CD33, which triggers the secretion
of the pro-inflammatory cytokine TNF-a by monocytes.
The mechanisms underlying the regulation of the TNF-
a release induced by CD33 down-regulation may involve
the generation of oxidative stress and the over-expres-
sion of SOCS3.
Methods
Participants
Twenty-one patients with type 2 diabetes and twenty-six
healthy subjects were enrolled in this study. Type 2 dia-
betes patients were invited to participate in the study at
the metabolic syndrome clinic of the National Institute
of Respiratory Diseases (INER) in Mexico City. Patients
with type 2 diabetes were diagnosed according to the
criteria of the American Diabetes Association (diagnosis
and classification of diabetes mellitus) [42]. Sixty millili-
ters of heparinized human peripheral venous blood was
obtained from consenting individuals. The study was
approved by the Institutional Review Board of the
National Institute of Respiratory Diseases.
Monocyte isolation
Mononuclear cells (PBMCs) were obtained from whole
blood by centrifugation using Lymphoprep
® (Nycomed-
Pharma, Oslo, Norway) [43]. Monocytes were enriched
by adherence and positive selection using MACS
® mag-
netic beads coupled to anti-human CD14 antibodies
(Miltenyi Biotech, Auburn, CA), according to the manu-
facturer’s recommendations. Purity was assessed by con-
ventional flow cytometry using anti-human CD14
antibodies; the cell preparations were routinely > 95%
monocytes. Monocyte viability was evaluated using the
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) reduction assay [44], and cell viability was
typically above 95%.
Media and cell culture
Monocytes were culturedi nR P M I1 6 4 0( C a m b r e x ,
Walkersville, MD) supplemented with 50 μg/ml genta-
micin sulfate, 2.0 mmol/l L-glutamine and 10% heat-
inactivated pooled human serum (Gemini Bioproducts,
Sacramento, CA) at 37°C in a 5% CO2 atmosphere.
Control medium contained 5.5 mmol/l D-glucose, and
high glucose conditions were achieved by supplementa-
tion with D-glucose (Sigma, St. Louis, MO) to obtain
final concentrations of 15, 20, 30, or 50 mmol/l D-glu-
cose. CD33 expression at the cell surface was examined
using flow cytometry. Monocytes from healthy volun-
teers were cultured with or without high concentrations
of glucose (15, 20, 30, or 50 mmol/l) for 7 days at 37°C
and 5% CO2 in ultra-low adherence 24-well cell culture
plates. Cells were then mechanically detached by pipet-
ting, and cell viability was typically greater than 95%, as
assessed by the MTT assay. The cells were then stained
using phycoerythrin (PE)-labeled anti-human CD33 and
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ciences, San Jose, CA, USA) or isotype controls. Fresh
monocytes from type 2 diabetes patients were also
stained. Cells were fixed with 1% paraformaldehyde, and
CD33 surface expression was analyzed by flow cytome-
try. The results are expressed as the mean fluorescence
intensity (MFI) of 20,000 acquired events. CellQuest
software version 3.1 (BD Biosciences) was used for the
analysis of the samples.
Total RNA extraction, cDNA synthesis and gene
expression analysis by qPCR
Monocytes from healthy volunteers were cultured with
5.5, 15, 30, or 50 mmol/l D-glucose for 7 days, and the
supernatants were collected and stored at -20°C for the
cytokine measurements. Cell viability was routinely
above 95%, as assessed by the MTT assay. Monocytes (5
×1 0
5 cells) were lysed in RTL buffer (Qiagen, German-
town, MD), and total RNA was column-isolated accord-
ing to the manufacturer’s recommendations (RNase
mini kit, Qiagen). RNA was also purified from freshly
isolated monocytes of patients with type 2 diabetes.
cDNA was prepared using a SuperScript First-Strand
Synthesis System for RT-PCR kit (Invitrogen, Carlsbad,
CA). Briefly, RNA was mixed with 10 mMdNTPs and
random hexamers and incubated at 65°C for 5 minutes.
The samples were then mixed with a Reverse Transcrip-
tase Mix (10× Reverse Transcriptase buffer, 25 mM
MgCl2, RNaseOUT recombinant ribonuclease inhibitor
and 0.1 M DTT). cDNA was synthesized using the
SuperScript II RT enzyme, and samples were placed in
an iCycler (Bio-Rad, Hercules, CA) with the following
cycling conditions: 25°C for 10 min, 42°C for 50 min
and 70°C for 10 min. The samples were also treated
with RNaseH.
The levels of CD33, IL-1b,I L - 6a n dT N F - a mRNA
were measured and normalized to that of the 18 S ribo-
somal RNA housekeeping gene. Real-time PCR reactions
were performed in duplicate wells, according to the pro-
tocols for Taqman gene assays for CD33
(Hs00233544_m1), TNF-a (Hs01000485_m1), IL-1b
(IHs0174097_m1), IL-6 (Hs00985639_m1), SOCS-3
(Hs01000485_g1), and 18 S ribosomal RNA (Applied
Biosystems, Carlsbad, CA). Briefly, a universal master
mix was added to the target gene primers and probes
(CD33, SOCS3, IL-1b,I L - 6 ,T N F - a, and 18 S ribosomal
RNA), DEPC water and cDNA samples (diluted 1:5),
and 25 μl from each reaction was added to a single well
of a 96-well optical reaction plate, which was then
sealed with optical adhesive film. Amplification reactions
were performed using an ABI Prism 7700 Sequence
Detection System (Applied Biosystems) with the follow-
ing conditions: 2 minutes at 50°C, 10 minutes at 95°C,
and 40 cycles consisting of 30 seconds at 95°C and one
minute at 62°C. Gene expression was normalized to that
of 18 S ribosomal RNA, and the results were analyzed
according to the ΔΔCt method and reported as the fold-
change in comparison to samples treated with 5.5
mmol/l D-glucose.
Pro-inflammatory cytokine production
Monocytes from healthy volunteers were cultured under
low or high glucose conditions (5.5 and 50 mmol/l D-
glucose, respectively) for 7 days at 5 × 10
5 cells/well in
24-well cell culture plates. Supernatants were collected
and frozen at -20°C for cytokine quantification. Secreted
cytokines were measured in the supernatants using a
pro-inflammatory cytometric bead array (CBA) kit (BD
Biosciences), according to the manufacturer’sr e c o m -
mendations. Cytokine concentrations were also quanti-
fied in the blood plasma of patients with type 2
diabetes. The cytokines measured included IL-1b,I L - 6 ,
I L - 8 ,I L - 1 0 ,I L - 1 2 p 7 0T N F - a. Cell Quest software was
used for the sample acquisition, and the data were ana-
lyzed using the Cytometric Bead Array software (CBA,
BD Biosciences). Values were extrapolated from a stan-
dard concentration curve and are expressed as pg/ml.
Monocyte culture in the presence of high glucose
concentrations and a-tocopherol
a-tocopherol was used as an antioxidant treatment in
monocyte cultures from healthy volunteers. a-toco-
pherol was diluted in pooled human serum (PHS) at a
concentration of 100 μmol/l and was protected from
light. Monocytes (5 × 10
5 cells) were pre-incubated for
20 minutes with 100 μmol/l a-tocopherol. Culture med-
ium with the high glucose concentration (50 mmol/l D-
glucose) was then added to simulate hyperglycemic con-
ditions in vitro. Cells were cultured for 7 days and were
then assessed for the production of reactive oxygen spe-
cies (ROS) and the expression of CD33.
Determination of reactive oxygen species (ROS)
generation
The fluorescent marker 5-(and 6-) carboxy-2,7-dichloro-
dihydrofluorescein diacetate (carboxy-HZDCF-DA;
Molecular Probes Inc., Eugene, OR, USA) was used to
assess ROS production. Carboxy-HZDCF-DA enters the
cell and is deacetylated, oxidized by reactive oxygen and
nitrogen species and converted to the fluorescent com-
pound 5-(and-6-) carboxy-2,7-dichlorofluorescein (car-
boxy-DCF). Following incubation under high glucose or
high glucose plus a -tocopherol conditions, the cells
were loaded with 10 μMcarboxy-HZDCF-DA for 30 min
a t3 7 ° Ci na na t m o s p h e r eo f5 %C O 2. The cells were
then stained using PE-labeled anti-human CD33 and
PerCP-labeled anti-human CD3 antibodies or isotype
controls. Carboxy-DCF fluorescence was evaluated in
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ROS production are expressed as the carboxy-DCF
mean fluorescence intensity (MFI) of 20,000 acquired
events.
Statistical analysis
The data are expressed as the means ± SD. Nonpara-
metric data were analyzed using the Mann Whitney test.
For multiple conditions and repeated measures, the
Friedman test and Dunn’s test were performed. The
data were analyzed using Prism software (GraphPad
Prism Software version 5.0), and statistical significance
was set at P < 0.05.
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